Ironwood Pharmaceuticals Inc. has a truly transformational event this December: the launch on December 17 of its first drug, linaclotide. Approved August 30 in the US for adults with irritable bowel syndrome and constipation (IBS-C) and/or chronic constipation, and in Europe on November 28 for IBS-C only, linaclotide is one of the most promising primary care drugs to come to market in recent years and, by all accounts, has potential to be a blockbuster.
Analysts estimate its global sales – the US brand name is Linzess – could peak at $2.7 billion or more...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?